RECEIVED CENTRAL FAX CENTER DEC 1 0 2007

Certificate

DEC 1 1 2007

of Correction

PATENT Client Reference Number: WH-14

Certificate of Transmission under 37 CFR 1.8 Thereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on December 9, 2007 Dr. O. M. (Sam) Zaghmout

Typed or printed name of person signing Certificate

Attachments: 1. form PTO 1050.2. Copy of the first page of the issued patent. 3. This cover letter (2 pages).

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Mukarram et al. Patent Number: 7,291,735

Issuance date: November 6, 2007 Application Serial Number: 10/564,364

Filing Date: 02-23-2006

Title: A Novel Process for the Manufacture of (+)-(S)-Clopidogrel Bisulfate Form- I

Examiner: Nizal S. Chandrakumar

Art Unit: 1625

MAIL STOP: POST ISSUE (Certificate of Correction Branch)

Date: December 9, 2007

REQUEST FOR CERTIFICATE OF CORRECTION

Honorable Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

The above patent contains a minor typographical error, as indicated on the attached Certificate of Correction (submitted in duplicate). This minor typographical error was inadvertent and without deceptive intent.

Accordance with the accompanying form PTO1050, please make specifically the following changes:

In the name of the first inventor:

Page 1 of 2, 11:00 AM, 12/9/2007. Request for Certificate of Correction. Applicant: Mukarrams et al. Application Serial Number: 10/564,364; Filing Date: 02-23-2006; Title: A Novel Process for the Manufacture of (+)-(S)-Clopidogrel Bisulfate Form- 1; Examiner: Nizal S. Chandrakumar, Art Unit: 1625. MAIL STOP: POST ISSUE.

DEC 11 2007

"Mohammed Siddiqui Jaweed Mukarram" -- Mohammed Jaweed Mukarram Siddiqui --

RECEIVED CENTRAL FAX CENTER

DEC 1 0 2007

CONCLUSION

Applicant respectfully requests the correction of the minor typographical error in sequence (order) listing in the name of the first inventor (first name, middle name, last name). This minor typographical error was inadvertent and without deceptive intent.

Should any official at the United States Patent and Trademark Office deem that any further action by the Applicant or Applicant's undersigned representative is desirable and/or necessary, the official is invited to telephone the undersigned at the number set forth below.

The Commissioner is herby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17 or credit any overpayment, to deposit account No. 503321. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, or otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 503321.

Respectfully submitted,

By: Sam Zaghmas

O. M. (Sam) Zaghmout Ph.D (Registration No. 51,286)

Contact Information:
Bio Intellectual Property Service (BIO IPS) LLC 8509 Kernon Ct, Lorton, VA 22079. USA (703) 550-1968 (Voice/Fax), Fax: (703-550-0409)

Page 2 of 2, 11:00 AM, 12/9/2007. Request for Certificate of Correction. Applicant: Mukarrams et al. Application Serial Number: 10/564,364; Filing Date: 02-23-2006; Title: A Novel Process for the Manufacture of (+)-(5)-Clopidogrel Bisulfate Form- 1: Examiner:Nizal S. Chandrakumar, Art Unit:1625. MAIL STOP: POST ISSUE.

PTO/SB/44 (IS-07:
Approved for use through 08/31/2015 CMB 681-6035
U.S. Petent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1895, no persons are required to reapond to a collection of information unless it displays a valid OMB control number.

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. 7,291,735

APPLICATION NO.: 10/564,364

November 6, 2007 ISSUE DATE INVENTOR(S) : Mukarram et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the name of the first inventor:.

"Mohammed Siddigui Jaweed Mukarram"-- Mohammed Jaweed Mukarram Siddigui --

MAILING ADDRESS OF SENDER (Please do not use customer number below):

BIO Intellectual Property Service (BIO IPS) LLC

8509 Kernon Ct, Lorton, VA 22079, USA,

751b collection of information in required by 37 CPR 1.322, 1323, and 1.324. The information is required to obtain or retain a benefit by the public which is to fold by the USPTO to process) an application. Confidentially is governed by 36 U.S.C. 122 and 37 CPR 1.14. This collection is estimated to take 1.0 hour complete including gethering, preparing, and submitting the completed application form to the duction and submitted the completed application form to the duction and submitted the completed application form to the duction and submitted the completed application form to the duction that burden, should be sent to the Chief Information Office of the Complete of th

PAGE 2/4 * RCVD AT 12/9/2007 11:03:57 AM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/16 * DNIS:2738300 * CSID:703 550 0409 * DURATION (mm-ss):02-00

BEST AVAILABLE COPY DEC 1 1 2007

PTO/SB/44 (09-07) Approved for use through 08/31/2010. OMB 0851-0035 U.S. Petent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. (Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. 7,291,735

Page 1 of 1

APPLICATION NO.: 10/564,364

ISSUE DATE

November 6, 2007

INVENTOR(S)

Mukarram et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the name of the first inventor:

"Mohammed Siddiqui Jaweed Mukarram"-- Mohammed Jaweed Mukarram Siddiqui --

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Dr. O. M. (Sam) Zaghmout

Bio Intellectual Property Service (BIO IPS) LLC

8509 Kernon Ct, Lorton, VA 22079, USA
This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will very depending upon the individual case. And comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PAGE 3/4 * RCVD AT 12/9/2007 11:03:57 AM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/16 * DNIS:2738300 * CSID:703 550 0409 * DURATION (mm-ss):02-00

DEC 11 2007



(12) United States Patent Mukarram et al.

(10) Patent No.: US

US 7,291,735 B2

(45) Date of Patent:

Nov. 6, 2007

- (54) PROCESS FOR THE MANUFACTURE OF (+)-(S)-CLOPIDOGREL BISULFATE FORM-1
- (75) Inventors: Mohammed Siddiqui Jaweed Mukarram, Aurangabad (IN);

Yekanathsa Arayind Merwade, Aurangabad (IN); Reyaz Anjum Khan,

Aurangabad (IN)

(73) Assignee: The Company of Wockhard Limited

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 11 days.

(21) Appl. No.: 10/564,364

(22) PCT Filed: Aug. 4, 2003

(86) PCT No.: PCT/IB03/03104

§ 371 (c)(1),

(2), (4) Date: Feb. 23, 2006

(87) PCT Pub. No.: WO2005/012300

PCT Pub. Date: Feb. 10, 2005

(65) Prior Publication Data

US 2006/0183907 A1 Aug. 17, 2006

(51) Int. Cl. *C07D* 471/02 (2006.01)

U.S. Cl. 546/114

(56) References Cited

U.S. PATENT DOCUMENTS

6,429,210 B1 * 8/2002 Bousquet et al. 514/301

* cited by examiner

(52)

Primary Examiner—D. Margaret Seaman
Assistant Examiner—Nizal S. Chandrakumar
(74) Attorney, Agent, or Firm—Bio Intellectual Property
Services (Bio IPS) LLC; O. M. (Sam) Zaghmout

(57) ABSTRACT

The present invention relates to a novel process for the manufacture of blood-platelet aggregation inhibiting agent. In particular, the present invention is directed to a process for the manufacture of Methyl-(+)-(S)- α -(2-chlorophenyl)-6,7-dihydrothieno [3,2-c]pyridine-S-(4H)acetate bisulfate form-f.

3 Claims, No Drawings